Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
NCT07274254Phase 3Recruiting
- Sponsor
- CHU de Nantes
- Start
- Jul 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial in vaso-occlusive crisis (VOC) comparing Experimental group: Lidocaine + standard of care with Control group: placebo + standard of care (2 arms). Primary endpoint: Cumulative parenteral opioid dose up to 28 days. Started Jul 2026; status: recruiting.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on NCT07274254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274254.